Advertisement

Educating Patients on Biomarker Testing

A panel of oncologists, patients, and a patient advocate discuss the emergence of comprehensive molecular testing in lung and thyroid cancer and consider how results can be used to inform treatment, as was done in 2 real-world cases highlighted.

EP. 1: Molecular Testing for NSCLC: Historical Perspectives

June 2nd 2021

Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, describes how molecular testing in non–small cell lung cancer has advanced and impacted treatment.

EP. 2: Personalized Medicine in Thyroid Cancer

June 2nd 2021

Lori J. Wirth, MD, of Massachusetts General Hospital, comments on the role of molecular testing to guide treatment decisions in thyroid cancer and explains how personalized medicine differs from standard treatment approaches.

EP. 3: Comprehensive Genomic Profiling in Lung and Thyroid Cancer

June 9th 2021

Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.

EP. 4: Best Practices When Testing With Comprehensive Genomic Profiling

June 9th 2021

Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.

EP. 5: The Emerging Role of Liquid Biopsies

June 16th 2021

Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

EP. 6: Educating Patients About Biomarker Testing

June 16th 2021

Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.

EP. 7: Molecular Testing and Shared Decision-Making

June 23rd 2021

Andrea Ferris, of the LUNGevity Foundation, explains why shared decision-making is important when recommending molecular testing to patients with lung or thyroid cancer and highlights resources provided through her organization that support patients and health care professionals.

EP. 8: Molecular Testing in Thyroid Cancer: Interpreting Results

June 23rd 2021

Lori J. Wirth, MD, describes what information she looks for from results of molecular testing that help inform treatment for her patients with thyroid cancer.

EP. 9: Molecular Testing and Novel Therapies for NSCLC

June 30th 2021

Benjamin Levy, MD, briefly describes the difference between driver mutations and immunotherapy biomarkers in non–small cell lung cancer and explains how decisions for immunotherapy or targeted therapy are made based on results of molecular assays.

EP. 10: Educating Patients on Germline and Somatic Testing

June 30th 2021

Drs Benjamin Levy and Lori J Wirth describe the differences between germline and somatic mutations, explain how these are detected and used to guide treatment for lung and thyroid cancer, and comment on counseling patients about concerns of hereditary findings.

EP. 11: Rationale for Molecular Testing in Real-World Scenarios

July 7th 2021

The rationale for testing 2 patients with cancer, Deborah and George, with molecular testing prior to managing their cases with novel therapy.

EP. 12: Receiving a Diagnosis of Advanced NSCLC

July 7th 2021

Deborah Kimmel describes the symptoms that led to a diagnosis of advanced non–small cell lung cancer and explains her journey to connecting with Dr Benjamin Levy and undergoing molecular testing.

EP. 13: George Labonte: Concerns Upon a Diagnosis of Medullary Thyroid Cancer

July 14th 2021

George Labonte explains what it was like receiving a diagnosis of medullary thyroid cancer and describes his experience being recommended for biomarker testing and concerns surrounding testing for germline mutations.

EP. 14: Waiting for Results and Processing Information From Biomarker Testing

July 14th 2021

Cancer patients, Deborah and George, reflect on their emotions while waiting to receive back results from biomarker testing and explain what it was like processing the information delivered by their test results as presented by their oncologists.

EP. 15: Becoming Informed About Comprehensive Genomic Profiling

July 21st 2021

Resources available to support patients and community oncologists who are interested in learning more and gaining access to comprehensive biomarker testing.

EP. 16: Access to Molecular Testing in the Community

July 21st 2021

Current barriers that impact patient access to comprehensive biomarker testing in the community and efforts underway to help advocate for increased accessibility to molecular assays moving forward.

EP. 17: Biomarker Testing: Centralized Vs Local Labs

July 28th 2021

The pros and cons of conducting pathology assessments for comprehensive biomarker tests in central laboratories versus local laboratories.

EP. 18: Precision Medicine and Clinical Trials

July 28th 2021

Online resources available to patients with lung or thyroid cancer who are considering participation in a clinical trial after undergoing comprehensive genomic profiling.

Advertisement
Advertisement